title: Osteonecrosis of the jaw related to bevacizumab.
authors: Memorial Sloan-Kettering Cancer Center, New York, NY, USA.
authors: Cherry L
authors: CL
authors: Estilo
authors: Monica
authors: M
authors: Fornier
authors: Azeez
authors: A
authors: Farooki
authors: Diane
authors: D
authors: Carlson
authors: George
authors: G
authors: Bohle
authors: Joseph M
authors: JM
authors: Huryn
mesh_terms: D020533:Angiogenesis Inhibitors / Q000009:adverse effects* / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000009:adverse effects* / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D001943:Breast Neoplasms / Q000188:drug therapy / Q000473:pathology; D018270:Carcinoma, Ductal, Breast / Q000188:drug therapy / Q000473:pathology; D005260:Female; D006801:Humans; D007571:Jaw Diseases / Q000139:chemically induced*; D008875:Middle Aged; D010020:Osteonecrosis / Q000139:chemically induced*
chemical_list: D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab